Diagnostics and treatment of chronic myelomonocytic leukemia in the years 2000-2013 - results from 2 hematologic centres
Abstract
Chronic myelomonocytic leukemia (CMML) is a clonal hematopoietic stem cell disorder classified as a myelodysplastic/myeloproliferative neoplasm that occurs mainly in the elderly. 35 patients (21 men, 14 women) with a median age of 67,5 years (47-85) were evaluated. Distribution by WHO 2008 classification showed CMML-1/CMML2 ratio (22/13) and by FAB classification myelodysplastic/myeloproliferative variant 19/16.
CPSS score was used for prognostic evaluation (WHO and FAB classification, cytogenetics, transfusion dependency). According to this scoring system 5 patients were from low, 13 from intermediate-1, 14 from intermediate-2 risk group and 2 patients were not evaluated.
Only six individuals from the whole cohort underwent allogeneic transplantation (ASCT), in 3 patients the signs of limited chronic GvHD (graft versus host disease) are observed, 3 patients died because of infections or disease progression. Survival analysis was performed using the Kaplan-Meier method.